Z FIERCE
`
`=Pharma
`
`<<)
`
`MANUFACTURING
`
`MARKETING
`
`PHARMA
`
`VACCINES
`
`TOPICS
`
`SPECIAL REPORTS
`
`Q
`
`FierceEvents
`
`FierceBiotech
`
`Jobs Resources Webinars
`
`industryEvents
`
`Subscribe W in
`
`Register for the Fierce Virtual Event: The long haul - How Pharma and Healthcare can thrive in
`2022
`oin speakers from Eli Lilly, Roche, Bayer,
`
`nssen
`
`and more
`
`nuar
`
`Special Reports
`
`The top 20 drugs by worldwidesalesin
`2020
`
`by Eric Sagonowsky| May 3, 2021 3:00am
`
`ON-DEMAND WEBINAR
`It's Time To Expect More
`From Your Patient
`Services Hub
`
`View Now
`
`GET THE
`
`NEWSLETTER
`
`The ranksof the industry's top drugs feature the biggest namesin the business, but behind the numbers
`are important trends to watch. (Getty/PraewBlackWhile)
`
`Pt
`
`While the global sales rankings of Big Pharma's superstar drugs naturally
`feature the biggest names in the business, new meds often pop upor old
`drugs exit the scene. And the moves withinthe list from year to year illustrate
`manyof the trends shaping pharmaona daily basis.
`
`The top three drugs—AbbVie's Humira, Merck's Keytruda and Bristol Myers
`Squibb’s Reviimid—held steady year over year. The first big change comes at
`No.4 with Bristol Myers and Pfizer's ascendant blood thinner Eliquis. In 2019,
`Bristol's checkpointinhibitor Opdivo held that spot. But the drug,initially a rival
`to Keytruda, couldn't keep pace with Merck and fell to No. 8 in 2020.
`
`Roche's aging cancer blockbuster Avastin took a dramatic plunge of its own.
`The drug generated $7.12 billion in 2019, enough for the No. 8 spot, but as
`biosim challengers gained steam,sales fell to $5 32billion in 2020. Avastin
`ended up at No. 14. Rituxan, another Roche blockbuster with new biosimilar
`competition, fell 7 spots to No. 17.
`
`Severalbig-selling drugs fell off the list altogether. Biogen's multiple sclerosis
`drug Tecfidera, under generic pressure, missed the cut in 2020, as did
`Roche's cancer blockbuster Herceptin and Gilead’s HIV drug Genvoya.
`
`Three drugs—AstraZeneca's cancer med Tagrisso, Pfizer and Astellas
`oncology offering Xtandi, and Roche's multiple sclerosis launch Ocrevus—all
`made the list for the first time.
`
`RELATED The top 20 drugs by globalsales in 2019
`
`As biosims and genericshit sales of several of the industry's top drugs,
`Remicade's 2020 performance shows that entrenched biologics can keep
`chuming even after competition hits the market. The drug has faced years of
`biosim competition but still generated blockbuster sales, holding onto the
`last spot in the global drug revenue rankings.
`
`That'slikely positive news for AbbVie, whichis bracing for competition to the
`world's top med—Humira—in 2023. Numerous biosim players are setto
`launch their copycats that year under deals with the branded drugmaker.
`Meanwhile, generics are also coming for BMS' Reviimid early next year, but in
`a volume-limited launch to start. BMS execs have said the company
`can grow despite the forthcoming copycats to the megablockbuster.
`
`Exhibit 2194
`
`Page 01 of 02
`
`emit
`
`Subscribe
`
`fre
`con
`FiercePharma and on
`f their trusted
`partners
`
`behalf
`
`Mylan v. Regeneron
`| P R2 02 1 -0 088 1
`U . S . Pat. 9 , 254 , 338
`
`Exhibit ?1 94
`
`Exhibit 2194
`Page 01 of 02
`
`

`

`Fierce Pharma compiled this list with assistance from EvaluatePharma.
`The intelligence firm provided global sales data for the industry's top drugs,
`including medicines that have multiple marketing partners, to our team in late
`March
`
`Let us know what you think—about this report and any others you'd like to
`see. — Eric Sagonowsky (email)
`
`1. HUMIRA 
`
`Exhibit 2194
`Page 02 of 02
`
`© 2021 Questex LLC. All rights reserved. 3 Speen Street, Suite 300, Framingham , MA 01701
`Reproduction in whole or part is prohibited.
`G E N E RA L
`H om e
`P r i v a c y
`Te rm s O f U s e
`R S S
`CON TAC T
`A d v e r t i s e
`A b o u t U s
`N EWS L E T T E RS
`S u b s c r i b e
`CON N EC T
`1. Humira
`2. Keytruda
`3. Revlimid
`4. Eliquis
`5. Imbruvica
`6. Eylea
`7. Stelara
`8. Opdivo
`9. Biktarvy
`10. Xarelto
`11. Enbrel
`12. Prevnar 13
`13. Ibrance
`14. Avastin
`15. Trulicity
`16. Ocrevus
`17. Rituxan
`18. Xtandi
`19. Tagrisso
`20. Remicade
`The top 20 drugs by worldwide sales in 2020
`Read More On
`Humira
`drug launch patent expirations
`